ESMO IMMUNO-ONCOLOGY CONGRESS 2021 INDUSTRY SATELLITE SYMPOSIUM

Off-the-shelf T-cell engaging therapies: the evolution of immuno-oncology in solid tumours

## Friday, 10 December, 13.15–14.15 (CET), Room C



Daniel W. Lee (Chair)

University of Virginia, USA



Alessandro Rambaldi University of Milan, Italy



Luis Paz-Ares National Cancer

Research Centre, Spain

Welcome and introduction to T-cell engaging therapies Daniel W. Lee

T-cell engaging therapies: leveraging haematological experience in the fight against solid tumours Alessandro Rambaldi

Clinical trial experience using a Bispecific T-cell Engager (BiTE®) in solid tumours

Luis Paz-Ares

Clinical management of cytokine release syndrome (CRS) with T-cell engaging therapies

Daniel W. Lee

All

Panel discussion: Future perspectives on off-the-shelf T-cell engaging therapies in oncology

## AMGEN<sup>®</sup> Oncology

SC-ELMAC-CP-00001 Amgen (Europe) GmbH, 6343 Rotkreuz, Switzerland. Date of preparation: November 2021. © 2021 Amgen Inc. All rights reserved.